Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurocognitive impact of hypofractionated temozolomide vs radiotherapy in elderly glioblastoma
2015-002751-10Phase 4Active
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- Sep 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of temozolomide in glioblastoma (GBM) (2 arms), sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: Hopkins Verbal Learning Test-Revised Total Recall at 6 months. Started Sep 2021; status: active.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2015-002751-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002751-10.